Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

VERU-100

Peptide · Antagonist of GnRH receptor (GNRHR) · developed by Veru

Phase 1/2 Most advanced trial (none active)

VERU Developer

1 Registered trials

What is VERU-100?

VERU-100 is a long-acting depot GnRH receptor antagonist decapeptide administered subcutaneously. It competes with GnRH for receptor binding in the anterior pituitary, inhibiting LH and FSH secretion and thereby suppressing testosterone production in males. It is studied in advanced prostate adenocarcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Peptide
Targets: GnRH receptor (GNRHR)
Mechanism: Antagonist of GnRH receptor (GNRHR)
Pathways: hormone production inhibition, LH/FSH suppression, testosterone suppression
Therapy area: Oncology
Developer: Veru Inc. (VERU)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04843319	Phase 1/2	Advanced Prostate Adenocarcinoma	Terminated	VERU

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Prostate Adenocarcinoma

More from Veru

Sabizabulin Phase 3

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the VERU page.

Follow VERU, the company behind VERU-100

See VERU's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VERU catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z